Literature DB >> 34165659

Efficacy of local salvage therapy for recurrent uterine cervical cancer after definitive radiotherapy.

Shinya Hiraoka1, Aya Nakajima2, Noriko Kishi2, Keiichi Takehana2, Hideki Hanazawa2, Yukinori Matsuo2, Takashi Mizowaki2.   

Abstract

BACKGROUND: The prognosis of patients with recurrence of uterine cervical cancer after definitive radiotherapy and the efficacy of local salvage therapy for recurrence were evaluated.
METHODS: We retrospectively reviewed 110 patients who were treated with definitive radiotherapy/chemoradiotherapy for uterine cervical cancer between 2008 and 2017 at our institution. Local salvage therapy was defined as any surgery or radiotherapy described in the medical record as intended for local control or cure.
RESULTS: We identified 25 patients who developed recurrence after definitive radiotherapy/chemoradiotherapy. The median follow-up time post-recurrence was 18.9 months. Thirteen patients (52%) reported recurrence in the isolated extra-pelvic lymph node (EPLN). The 2-year overall survival after first recurrence (OSr) for patients with isolated EPLN recurrence was 83.1%, compared to that of 31.2% for patients with other patterns of recurrence (p < 0.001). The 2-year OSr for patients who underwent local salvage therapy was 75.2%, whereas that for patients who did not undergo therapy was 41.6% (p = 0.04). Among patients who had recurrence in the isolated EPLN and received local salvage therapy, 20% of the patients reported recurrence in visceral and/or bone metastases after local salvage therapy, and 50% of the patients experienced another EPLN recurrence, which was salvaged with repeating local therapy.
CONCLUSIONS: Patients with uterine cervical cancer with isolated EPLN recurrence had favorable prognoses. The indications of local salvage therapy should be considered, especially for patients with isolated EPLN recurrence.

Entities:  

Keywords:  Chemotherapy; Local salvage therapy; Oligometastases; Radiotherapy; Recurrent uterine cervical cancer

Year:  2021        PMID: 34165659     DOI: 10.1007/s10147-021-01974-0

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  25 in total

1.  Cancer incidence and incidence rates in Japan in 2007: a study of 21 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project.

Authors:  Ayako Matsuda; Tomohiro Matsuda; Akiko Shibata; Kota Katanoda; Tomotaka Sobue; Hiroshi Nishimoto
Journal:  Jpn J Clin Oncol       Date:  2013-01-07       Impact factor: 3.019

2.  Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer.

Authors:  Hyun Ju Kim; Jee Suk Chang; Woong Sub Koom; Kyu Chan Lee; Gwi Eon Kim; Yong Bae Kim
Journal:  Gynecol Oncol       Date:  2018-09-06       Impact factor: 5.482

3.  Evidence-based therapy for recurrent cervical cancer.

Authors:  Bradley J Monk; Krishnansu S Tewari
Journal:  J Clin Oncol       Date:  2014-07-28       Impact factor: 44.544

4.  Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  C Marth; F Landoni; S Mahner; M McCormack; A Gonzalez-Martin; N Colombo
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

5.  Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.

Authors:  Takafumi Toita; Ryo Kitagawa; Tetsutaro Hamano; Kenji Umayahara; Yasuyuki Hirashima; Yoichi Aoki; Masahiko Oguchi; Mikio Mikami; Ken Takizawa
Journal:  Gynecol Oncol       Date:  2012-04-30       Impact factor: 5.482

6.  Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2).

Authors:  Takafumi Toita; Shingo Kato; Yuzuru Niibe; Tatsuya Ohno; Tomoko Kazumoto; Takeshi Kodaira; Masaaki Kataoka; Naoto Shikama; Masahiro Kenjo; Sunao Tokumaru; Chikako Yamauchi; Osamu Suzuki; Hideyuki Sakurai; Hodaka Numasaki; Teruki Teshima; Masahiko Oguchi; Yoshikazu Kagami; Takashi Nakano; Masahiro Hiraoka; Norio Mitsuhashi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-04       Impact factor: 7.038

7.  Prognostic Importance of the Site of Recurrence in Patients With Metastatic Recurrent Cervical Cancer.

Authors:  Tae Hun Kim; Moon-Hong Kim; Beob-Jong Kim; Sang-Il Park; Sang-Young Ryu; Chul-Koo Cho
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-03-27       Impact factor: 7.038

8.  Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.

Authors:  Bradley J Monk; Michael W Sill; D Scott McMeekin; David E Cohn; Lois M Ramondetta; Cecelia H Boardman; Jo Benda; David Cella
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

9.  Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update.

Authors:  Fabio Landoni; Alessandro Colombo; Rodolfo Milani; Franco Placa; Vanna Zanagnolo; Costantino Mangioni
Journal:  J Gynecol Oncol       Date:  2017-02-24       Impact factor: 4.401

10.  HPV Vaccination and the Risk of Invasive Cervical Cancer.

Authors:  Jiayao Lei; Alexander Ploner; K Miriam Elfström; Jiangrong Wang; Adam Roth; Fang Fang; Karin Sundström; Joakim Dillner; Pär Sparén
Journal:  N Engl J Med       Date:  2020-10-01       Impact factor: 91.245

View more
  1 in total

1.  Comprehensive Expression Profiling and Molecular Basis of CDC28 Protein Kinase Regulatory Subunit 2 in Cervical Cancer.

Authors:  Li Qin; Xiaoqiong Luo; Xiao Qin; Hongbao Huang; Lianling Zhang; Shengcai Chen; Xiaoqin Wu; Bingsheng Huang; Jian Pan; Jingxi Wei
Journal:  Int J Genomics       Date:  2022-07-28       Impact factor: 2.758

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.